Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03927976 · ClinicalTrials.gov registry record · NA

Feasibility of a Culturally-Specific Video Text Cessation Intervention With AA Quitline Callers

A NA study of Tobacco Use Cessation, sponsored by Case Comprehensive Cancer Center.

Completed
Registry status
NA
Development phase
35
Enrollment target
1
Study location

NCT03927976 is a NA study of Tobacco Use Cessation that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 35 participants, below the 884-participant average among 36 other Tobacco Use Cessation trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03927976, a NA study of Tobacco Use Cessation, has completed, sponsored by Case Comprehensive Cancer Center.

COMPLETED
Registry status
NA
Development phase
35 participants
Enrollment target
1
Study location

Study Summary

Assess the feasibility and acceptability of delivering an mHealth tobacco intervention among state quitline enrollees.

Conditions Studied

Interventions

  • BEHAVIORAL Path2Quit - culturally specific text message intervention

Study Locations (1)

Ohio

  • Case Western Reserve University - Cleveland

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2019-04-10
Est. Completion 2020-02-10
Phase NA

Sponsor

Case Comprehensive Cancer Center

407 total trials

What the Registry Record Tells You About NCT03927976

The ClinicalTrials.gov registry entry for NCT03927976 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 884-participant average among 36 other Tobacco Use Cessation trials with a reported enrollment target (96% lower). The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Tobacco Use Cessation appearing as the primary indexed condition, and to 1 intervention - of which Path2Quit - culturally specific text message intervention is the first listed.

NCT03927976 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT03927976 about?

NCT03927976 is a clinical study titled "Feasibility of a Culturally-Specific Video Text Cessation Intervention With AA Quitline Callers". Assess the feasibility and acceptability of delivering an mHealth tobacco intervention among state quitline enrollees.

What is the current status of trial NCT03927976?

This trial is currently completed. It is a NA study. The enrollment target is 35 participants. The study started on 2019-04-10. Estimated completion is 2020-02-10.

What conditions does trial NCT03927976 study?

This clinical trial studies the following conditions: Tobacco Use Cessation.

What interventions are being tested in trial NCT03927976?

The interventions under investigation include: Path2Quit - culturally specific text message intervention (BEHAVIORAL).

Who is sponsoring clinical trial NCT03927976?

This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03927976 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Tobacco Use Cessation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.